HIKMA Pharmaceuticals PLC
HIK | IL
Overview
Corporate Details
- ISIN(s):
- GB00B0LCW083
- LEI:
- 549300BNS685UXH4JI75
- Country:
- United Kingdom
- Address:
- 1 New Burlington Place, W1S 2HR London
- Website:
- https://www.hikma.com/home/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Hikma Pharmaceuticals PLC is a global pharmaceutical company that is dedicated to providing high-quality, affordable medications to patients worldwide. With its headquarters in London, UK, and operations in the Middle East, Africa, Europe, and the United States, Hikma has established itself as a leader in the pharmaceutical industry. The company has a diversified product portfolio that includes branded, generic, and injectable pharmaceuticals. Its focus is on developing and manufacturing innovative solutions for complex diseases, such as oncology, respiratory, and injectables.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-13 14:51 |
Director's Dealing
Director/PDMR Shareholding
|
English | 17.9 KB | |
| 2025-08-08 13:59 |
Director's Dealing
Director/PDMR Shareholding
|
English | 14.6 KB | |
| 2025-08-07 08:00 |
Earnings Release
Half-year Report
|
English | 884.0 KB | |
| 2025-07-09 10:00 |
Report Publication Announcement
Notice of Results
|
English | 12.9 KB | |
| 2025-07-07 10:16 |
Report Publication Announcement
Publication of Offering Circular
|
English | 8.0 KB | |
| 2025-06-05 15:05 |
Director's Dealing
Director/PDMR Shareholding
|
English | 14.4 KB | |
| 2025-06-03 14:02 |
Director's Dealing
Director/PDMR Shareholding
|
English | 89.1 KB | |
| 2025-05-29 08:00 |
Capital/Financing Update
Fitch upgrades Hikma to ‘BBB’
|
English | 11.3 KB | |
| 2025-05-15 13:00 |
Earnings Release
Medium-term Group guidance ahead of US site visit
|
English | 12.5 KB | |
| 2025-05-08 11:48 |
Regulatory News Service
S&P upgrades Hikma to ‘BBB’
|
English | 11.3 KB | |
| 2025-05-08 09:21 |
Legal Proceedings Report
Settlement agreement for Xyrem® US lawsuits
|
English | 15.2 KB | |
| 2025-04-30 14:21 |
Director's Dealing
Director/PDMR Shareholding
|
English | 27.3 KB | |
| 2025-04-24 18:16 |
Post-Annual General Meeting Information
Special Business passed at AGM
|
English | 329.0 KB | |
| 2025-04-24 16:55 |
Post-Annual General Meeting Information
Result of AGM
|
English | 48.9 KB | |
| 2025-03-19 11:10 |
Pre-Annual General Meeting Information
Annual Financial Report and Notice of AGM
|
English | 10.4 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ABIVAX | France | ABVX | |
|
Addex Therapeutics Ltd | Switzerland | ADXN | |
|
AegirBio AB | Sweden | AEGIR | |
|
AGRONOMICS LIMITED | Isle of Man | ANIC | |
|
AIREA PLC | United Kingdom | AIEA | |
|
Alkaloid AD | North Macedonia | ALK | |
| Alma Yesodot Ltd. | Israel | KVSR | ||
|
Amphastar Pharmaceuticals Inc. | United States of America | AMPH | |
| Ananda Pharma Plc | United Kingdom | N/A | ||
|
AnGes, Inc. | Japan | 4563 |